Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects

Influenza Disease Clinical Trial

Official title:

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-elderly Adult and Elderly Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00918268
• Other study ID #: V71_10S
• Secondary ID: 2009-010598-19
• Status: Completed
• Phase: Phase 2
• First received: June 9, 2009
• Last updated: April 20, 2012
• Start date: June 2009
• Est. completion date: July 2009

Study information

• Verified date: April 2012
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Italy: Ethics Committee delegated by AIFA
• Study type: Interventional

Clinical Trial Summary

Annual trial for registration influenza vaccine with the strain composition for season 2009/2010.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age or older, mentally competent, willing and able to give written informed consent prior to study entry;

• able to comply with all the study requirements;

• in general good health as determined by:medical history, physical examination and- clinical judgment of the investigator Written informed consent must be obtained for all the subjects before enrollment into the study after the nature of the study has been explained.

Exclusion Criteria:

• They have any serious chronic or acute disease (in the judgment of the investigator) including but not limited to:

1. Cancer, except for localized skin cancer;

2. Advanced congestive heart failure

3. Chronic obstructive pulmonary disease (COPD);

4. Autoimmune disease (including rheumatoid arthritis);

5. Acute or progressive hepatic disease;

6. Acute or progressive renal disease;

7. Severe neurological or psychiatric disorder

8. Severe asthma

• They have history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate);

• They have a known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:- receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;receipt of immunostimulants,receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study and suspected or known HIV infection or HIV-related disease;

• They have a known or suspected history of drug or alcohol abuse;

• They have a bleeding diathesis or condition associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;

• Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing age do not plan to use acceptable birth control measures, for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom or diaphragm), intrauterine device (IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry;

• Within the past 12 months, they have:- received more than one injection of influenza vaccine

• Within the past 6 months, they have:-had laboratory confirmed influenza disease,- received influenza vaccine;

• Within the past 4 weeks they have received:-another vaccine;-any investigational agent;

• They have any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days;

• They have experienced fever (i.e., axillary temperature= 38°C) within the last 3 days;

• They are taking part in another clinical study;

• They have any condition which, in the opinion of the investigator,might interfere with the evaluation of the study objectives;

• They are severely obese with Body Mass Index (BMI) > 35;

• Site personnel involved in the evaluation of safety and their immediate relatives are excluded from participation.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza Disease
• Influenza, Human

Intervention

Biological:
• Influenza vaccine
One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010

Locations

Country	Name	City	State
Italy	Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via dei Vestini	Chieti
Italy	Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37 ----- Satellite sites: (a) Distretto Sanitario di Base, Via Don Minzoni, Lanciano (CH) and (b) Distretto Sanitario di Base, Via Polidoro, Fossacesia (CH))	Lanciano
Italy	Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48	Pianiga

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Vaccines

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in non-elderly adult and elderly subjects		21(-1/+5) days	Yes
Primary	Evaluation of safety of a single intramuscular injection of influenza vaccine in non elderly adult and elderly subjects		21(-1/+5) days	Yes